On May 16, 2019 Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, reported the results of the effect of STP705 on the growth of HuCCt-1 (a human cholangiocarcinoma cell line) as a xenograft tumor in nude mice (Press release, Sirnaomics, MAY 16, 2019, View Source [SID1234536452]). The work is published as an online abstract at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice

Cholangiocarcinoma (CCA) is the second most common form of incurable hepatobiliary cancer and represents a massive health care burden worldwide with no effective treatment. Over expression of the genes for TGF-β1 and COX-2 have been well-characterized as playing key roles in tumorigenesis of CCA. STP705 consists of a combination of 2 siRNAs silencing the TGF-β1 and COX-2 genes delivered using a polypeptide nanoparticle delivery system based on Histidine-Lysine co-Polymer (HKP). We have demonstrated that STP705 inhibits the growth of HuCCt-1 xenograft tumors in nude mice (a human cholangiocarcinoma model) and the data is presented in the abstract.